IN THIS ISSUE

The Guiding Light...
Learn about the Meeting theme and trailblazers who continue to inspire it.

200+ CE and Scientific Sessions
Get the full scope of what’s being offered in Anaheim.

Don’t Forget Your Mouse Ears
Learn about exclusive discounts available for Annual Meeting attendees!

Preview Magazine > Issue 2
You Now Have More Options When it Comes to Cardiac PET Imaging

- Automated quality control for lab efficiency
- Engineered for user confidence and efficiency with a 30 liter volume and a long 60-day shelf life
- Accurate patient specific infusion options including constant-activity and weight-based dosing
- Built-in safety controls to protect staff and patients

Contact your local sales representative to discuss business solutions tailored to YOUR needs or for more information visit www.draximage.com

Important Safety Information

Indication
RUBY-FILL Rubidium Rb 82 Generator is a closed system used to produce rubidium Rb 82 chloride injection for intravenous use. Rubidium Rb 82 chloride injection is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.

WARNING: UNINTENDED STRONTIUM 82 (Sr 82) AND STRONTIUM 85 (Sr 85) RADIATION EXPOSURE

Please see full prescribing information for complete boxed warning. Unintended radiation exposure occurs when the levels of Sr 82 or Sr 85 in the Rubidium Rb 82 chloride injection exceed specific limits.

Perform generator eluate tests:
1. Determine Rb 82, Sr 82, Sr 85 levels in the eluate:
   - Once daily, prior to any drug administration, and
   - With additional daily tests after detection of an Alert Limit.
2. Stop use of the generator at its Expiration Limit.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.

RUBY-FILL is a registered trademark used under license by Jubilant DraxImage, Inc.

Jubilant DraxImage Inc.
16751 Trans-Canada Highway, Kirkland, Quebec, Canada H9H 4J4
Phone: 1.888.633.5343 / 514.630.7080 Fax: 1.866.431.4288 / 514.694.3865
www.draximage.com

2019CARD081

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.

RUBY-FILL is a registered trademark used under license by Jubilant DraxImage, Inc.

Jubilant DraxImage Inc.
16751 Trans-Canada Highway, Kirkland, Quebec, Canada H9H 4J4
Phone: 1.888.633.5343 / 514.630.7080 Fax: 1.866.431.4288 / 514.694.3865
www.draximage.com

2019CARD081
SATURDAY
June 22, 2019
6:30–9:00 am
Hot Trot 5K Run/Walk
7:30 am–3:00 pm
Categorical Seminars
8:00 am–4:45 pm
Nuclear Medicine Review Course (NMRC) – Day 1
8:00 am–4:15 pm
SNMMI-TS CE Courses
8:00 am–4:45 pm
Student Technologist Registry Review (STRR) – Day 1
9:00 am–4:45 pm
SNMMI CE Courses
5:00–8:00 pm
Welcome Reception: Exhibit and Poster Hall Opening
8:00 pm–End
User Meetings

SUNDAY
June 23, 2019
6:00–8:00 am
User Meetings
8:00–9:30 am
Nuclear Medicine Review Course (NMRC) – Day 2
8:00–9:30 am
Opening Plenary Session: Henry N. Wagner Jr., MD, Lectureship
9:30 am–4:30 pm
Exhibit Hall
10:00 am–5:30 pm
SNMMI CE Courses
10:00 am–6:15 pm
SNMMI CE Courses & Scientific Abstract Presentations
2:00–3:00 pm
Young Investigator (YIA) and Young Professionals Committee (YPC) Awards Ceremony
3:00–4:30 pm
“Meet the Author” Session I
4:45–6:15 pm
Henry N. Wagner Jr., MD, Highlights Symposium
6:15–7:15 pm
Closing Celebration
7:15 pm–End
User Meetings

MONDAY
June 24, 2019
6:00–8:00 am
User Meetings
8:00–9:30 am
SNMMI Business Meeting and Special Plenary/Cassen Lectureship
9:00 am–6:00 pm
Scientific & Educational Poster Hall
9:30 am–4:30 pm
Exhibit Hall
10:00–11:30 am
Emerging Technologies Session (CMIIT) #2 (Non-CE)
10:00 am–4:30 pm
SNMMI-TS CE Courses
10:00 am–6:15 pm
SNMMI CE Courses & Scientific Abstract Presentations
2:00–3:00 pm
Young Investigator (YIA) and Young Professionals Committee (YPC) Awards Ceremony
3:00–4:30 pm
“Meet the Author” Session II
3:00–4:30 pm
Computer and Instrumentation Basic Science Summary Session
4:45–6:15 pm
SNMMI-TS Business Meeting
6:00 pm–End
User Meetings

TUESDAY
June 25, 2019
6:00–8:00 am
User Meetings
8:00 am–2:00 pm
SNMMI CE Courses
8:00 am–4:30 pm
CT and MRI Case Reviews
8:00 am–4:30 pm
SNMMI CE Courses & Scientific Abstract Presentations
9:00 am–5:00 pm
Scientific & Educational Poster Hall
9:30 am–4:30 pm
SNMMI-TS CE Courses
10:00 am–6:15 pm
SNMMI CE Courses & Scientific Abstract Presentations
2:00–3:00 pm
Young Investigator (YIA) and Young Professionals Committee (YPC) Awards Ceremony
3:00–4:30 pm
“Meet the Author” Session III
4:45–6:15 pm
Henry N. Wagner Jr., MD, Highlights Symposium
6:15–7:15 pm
Closing Celebration
7:15 pm–End
User Meetings

Register Today
snmmi.org/2019preview2
More than 125 CE sessions will be available at the SNMMI 2019 Annual Meeting, with the opportunity to earn more than 25 CE Credits. Sessions include:

**Anatomical Imaging**
- Cardiac PET Workshop
- Cardiac: PET/CT and SPECT/CT
- Cardiac: Molecular Imaging of Common and Uncommon Musculoskeletal Diseases
- Cardiac: Total Body PET and Its Applications
- Cardiac: The Success Stories
- Cardiac: History Committee Session

**Cardiovascular/ Molecular Imaging & Intervention**
- Cardiovascular: Noninvasive Evaluation of CAD
- Cardiovascular: Cardiac Amyloidosis: Diagnosis and Management
- Cardiovascular: Aortic Valve: The Success Stories
- Cardiovascular: Cardiac Imaging Quantification

**Cardiovascular**
- Cardiac: Imaging Quantification

**Career Development/Leadership**
- Private Practice: Community-Based Physicians
- Private Practice: Community-Based Physicians
- Private Practice: Community-Based Physicians
- Private Practice: Community-Based Physicians

**CE Sessions**

**Saturday, June 22, 2019**
- Target Identification: Nuts and Bolts: Using Linchpin-177 Dotatate
- Molecular Imaging for Immunochemistry
- Molecular Imaging in Drug Development
- New PET Radiopharmaceuticals—Read with the Experts

**Sunday, June 23, 2019**
- Molecular Targeting with PET: Target Identification
- Molecular Imaging for Immunochemistry
- Molecular Imaging in Drug Development
- New PET Radiopharmaceuticals—Read with the Experts

**Monday, June 24, 2019**
- Cancer Immunotherapy: Current State and Future Directions
- Current State of Development of New Therapeutic Agents
- Radiopharmaceuticals: Diagnosis and Therapy
- Radiation Dosimetry
- Radiation Therapy: Nuts and Bolts

**Tuesday, June 25, 2019**
- Radiopharmaceuticals: Diagnosis and Therapy
- Radiation Therapy: Nuts and Bolts

**Neurosciences**
- Can We Use Quantitative PET in Clinical Practice?
- Brain Imaging Read with the Experts

**Oncology and Therapy**
- Prostate Cancer: Nuts and Bolts: Diagnosis and Therapy
- Differentiated Thyroid Cancer Theranostics Practice: Present and Future of PRRT in the Treatment of Neuroendocrine Tumors
- Radiation Dosimetry in Neuroendocrine Tumors
- Radiation Therapy Nuts and Bolts

**Pediatrics**
- Advanced Pediatric Imaging
- Pediatric PET/MR

**Technology-Focused**
- Quality in Nuclear Medicine
- General Nuclear Medicine Theranostics
- Leadership and Mentoring: Becoming a Positive Role Model
- Radiopharmaceuticals: Drug Development
- Radiopharmaceuticals: Drug Development
- PET/CT: Assessment Response
- V/Q Lung Imaging: Pulmonary Embolism and Beyond
- Best Clinical Practice
- ACR/NRQI Update Session
- Diagnostic and Therapy
- Radiation Therapy Nuts and Bolts

**Instrumentation and Data Analysis**
- Nuts and Bolts: State of the Art in Physics, Instrumentation, Performance and Clinical Applications
- Innovation in PET Instrumentation Enable by Made-in-Japan Technologies

As of March 31, 2019. Please note, new session information is being added daily. Visit www.snmmi.org/2019preview2 for the most up-to-date session listings.
The SNMMI 2019 Annual Meeting’s scientific program includes 80 scientific sessions featuring 740 oral abstract presentations, and a scientific poster hall with more than 1,100 posters.

### Scientific Sessions

**Saturday, June 22, 2019**
- **Cardiovascular**
  - Metabolism & Molecular Imaging (Basic Science)
- **General Clinical Specialties**
  - Renal/Hypertension
- **Molecular Targeting Probes**
  - Center for Molecular Imaging Innovation & Translation (CMITT)
- **Neurosciences**
  - Brain Imaging Council YIA Symposium
- **Oncology, Basic**
  - PSMA Based Agents (Oncology, Basic Science)
- **Oncology, Clinical**
  - Multiple Myeloma
- **Physics, Instrumentation, Data Sciences**
  - Image Generation: ECT & CT

**Sunday, June 23, 2019**
- **Cardiovascular**
  - Cardiovascular YIA Symposium
  - Advances in Clinical Utility of Myocardial Blood Flow Quantification
- **General Clinical Specialties**
  - Musculoskeletal Pediatrics
- **Molecular Targeting Probes**
  - Novel Radiometal & Fluorine-18 Chemistry
  - Radiopharmaceutical Sciences (RPSC) YIA Symposium
- **Neurosciences**
  - Neurosciences-Basic Science I
  - Neurosciences-Basic Science II
- **Oncology, Basic**
  - Center for Therapy Excellence YIA Symposium
  - Technical Advances & Quantification
- **Oncology, Clinical**
  - Lung Cancer I: Molecular Biomarkers & Molecular Imaging Signatures
  - Lung Cancer II: Targeted Therapies, Response to Treatment, and Prognosis
- **Physics, Instrumentation, Data Sciences**
  - Physics, Instrumentation & Data Sciences YIA Symposium
  - Image Generation: Quantitative PET/MR

**Monday, June 24, 2019**
- **Cardiovascular**
  - Perfusion & Flow Quantification
  - Improving Prognostication from Cardiovascular Nuclear Imaging
  - Invasive Cardiomyopathies & Infection Imaging
- **General Clinical Specialties**
  - Outcomes/Infectious Disease/ Pulmonary II
  - Outcomes/Infectious Disease/ Pulmonary II
  - Gastroenterology
- **Molecular Targeting Probes**
  - Radiopharmacy: GMP Synthesis and Quality Control Improvements
  - Dosimetry
  - Novel Radiosynthesis for Cancer Applications
- **Neurosciences**
  - Amyloid & Tau PET
  - Novel Brain Imaging Targets
  - Brain PET/MRI
- **Oncology, Basic**
  - Oncology, Basic & Translation I
  - Oncology, Basic & Translation II
- **Oncology, Clinical**
  - Other Solid Tumors/Hematologic Malignancies I (Clinical)
  - GI-Pancreatic & Neuroendocrine (Oncology, Clinical)
  - Other Solid Tumors/Hematologic Malignancies II (Clinical)
  - Gynecological Cancers
  - Breast Cancer: Novel Tracer & Practice Advances (Oncology, Clinical)
- **Physics, Instrumentation, Data Sciences**
  - PET Image Quality (Image Generation)
  - New System Design & Emerging Technology I (Instrumentation)
  - PET Image Quality & Quantitative Imaging (Instrumentation)

**Track**
- **Cardiovascular**
- **General Clinical Specialties**
- **Molecular Targeting Probes**
- **Neurosciences**
- **Oncology, Basic**
- **Oncology, Clinical**
- **Physics, Instrumentation, Data Sciences**

**Scientific Papers and Posters**
- Attend scientific sessions featuring oral and poster presentations by authors of accepted abstracts. Oral sessions are 90 minutes in duration and include up to 7 presentations per session with sufficient time allotted to answer questions from attendees, while poster sessions offer similar content with flexible viewing times. Investigators will be on-hand during the “Meet the Author” poster sessions to discuss their research.

**Poster Hall Mixer**
- The Radiopharmaceutical Sciences Council (RPSC) and the Center for Molecular Imaging Innovation and Translation (CMITT) invite you to attend the Annual Poster Mixer. This popular event is your opportunity to view hundreds of scientific posters, interact with authors, and build your network!

**Poster Awards**
- At the start of the Tuesday “Meet the Author” poster session, poster finalists (1st, 2nd, and 3rd place winners) for scientific tracks, as well as educational exhibits, will be recognized for their work. Certificates will be presented to each finalist by the Chair of the Scientific Program Committee, and each winning poster will be identified by a prize ribbon affixed to the poster board.

**International Best Abstract Awards**
- More than 60 countries are represented each year among the scientific abstracts featured during the annual meeting. SNMMI will again recognize the best scientific abstract from each submitting country.
THE PARK AFTER DARK

It’s easy to feel wiped out after a day full of learning and networking but hang in there! Some of the best Disneyland® Park attractions take place after sunset.

> At Disneyland® Park
Remember... Dreams Come True Fireworks Spectacular Narrator Julie Andrews takes you on an amazing journey through the various lands of Disneyland® for one of the park's best-loved fireworks extravaganzas of all time: Remember... Dreams Come True. This dazzling 16-minute spectacular first delighted park visitors as the evening highlight of the 50th anniversary of Disneyland® in 2005 and returned in 2017 with all your favorite songs and familiar phrases from some of the most popular attractions at Disneyland®, past and present. From the beloved melody of “When You Wish Upon a Star,” to the Haunted Mansion's mischievous “Grim, Grinning Ghosts,” to the instantly recognizable and iconic theme from “Star Wars,” the skies over Disneyland® come alive each night with a dazzling array of fireworks, flames and lasers to create memories you and your family will cherish for years to come!

> All Aboard
This summer, the classic Disneyland Railroad reopens to offer guests a relaxing 18-minute ride around the park. Originally opened in 1955, the Disneyland Railroad continues to be one of the park’s most popular attractions, carrying passengers through the Grand Canyon, a prehistoric landscape complete with life-size dinosaurs, and the depths of Splash Mountain to one of four convenient stops within the park: Main Street, U.S.A., Tomorrowland, New Orleans Square or Mickey’s Toontown — all on one of five restored, working narrow-gauge trains.

> Fantasmic! Returns to Ignite the Night
This summer, the skies over Rivers of America will once again come alive with the sights and sounds of Mickey’s imagination as Fantasmic!, the parks’ most beloved nighttime spectacular, returns! Watch Mickey use the power of love to defeat classic Disney villains during this one-of-a-kind cacophony of music, lasers, high-resolution digital film sequences, pyrotechnics and fiber optics leading up to the spectacular finale featuring a massive, 45-foot fire-breathing dragon!

courtesy of visitanaheim.org

Discounts are available exclusively for Annual Meeting attendees.
Learn more at: www.snmmi.org/AM_ears

NETWORKING

In addition to close to 200 CE and scientific sessions, the SNMM Annual Meeting is your chance to meet face-to-face with your colleagues from across the globe. Be sure to make time to attend these great events and networking opportunities throughout the meeting!

> Saturday Evening Opening Ceremony
Taking place just prior to the Welcome Reception in the Exhibit Hall, you’ll get an overview of the meeting, learn about sunny southern California, the host city of Anaheim, and how to get the most out of your visit. You’ll also hear from this year’s highlight country about the latest research and innovations happening in Canada.

> “Drink and Think”
These informal gatherings at local pubs and bars on Monday evening will be organized around particular areas of interest. This will give you an opportunity to relax with colleagues and new friends to discuss issues of common interest.

> Plenary Sessions and Henry N. Wagner, Jr., MD Highlights Symposium
These must-attend events highlight keynote speakers, significant awards and accomplishments, the SNMM business meeting, installation of the new SNMMI president, a synopsis of research during the Annual Meeting, announcement of the Image of the Year and much, much more.

> Exhibit/Poster Hall Opening & Welcome Reception
Hosted by the SNMMI 2019 Annual Meeting Exhibitors
Packed with the latest trends and technology related to the fields of molecular imaging and nuclear medicine; don’t miss your first chance to network with thousands of industry colleagues, industry leaders, and representatives from major manufacturers in the Exhibit Hall. The Exhibit Hall Grand Opening is the perfect kick-off event to four days of learning and science! Enjoy hors d’oeuvres, drinks, and music at this must-attend event!

> “On to New Orleans” Celebration
Join your colleagues and the SNMMI leadership following the Henry N. Wagner, Jr., MD Highlights Symposium, for a special toast to help kick off the countdown to the SNMMI 2020 Annual Meeting in New Orleans, Louisiana!

5th Annual “Hot Trot 5K” Run/Walk
Proceeds benefit the SNMM-TS Professional Development and Education Fund, supporting the advancement of molecular and nuclear medicine technologists. A portion of registration proceeds will also support Project Access, providing low income families the tools needed to break the cycle of poverty. Exercise your body before you exercise your brain! Sign up today.
Sponsorship opportunities are also available. Visit www.snmmi.org/HotTrot5K for info.

courtesy of visitanaheim.org
Explore the latest technologies, witness ground-breaking new products and services, and connect with more than 165 top industry suppliers ready to help furnish your organization with the tools and equipment needed to best serve you and your patients.

**THE SNMMI 2019 EXHIBIT HALL**

- **Current Exhibitors**
  - **Sunday and Monday in the training showcase theater!**
  - Learn directly from top suppliers. These thirty-minute, interactive Training Showcase 30-minute sessions will be participating – so be sure to visit them all! Up to 20 companies be eligible to win the $300 cash prize. Two Hall Hours. Be sure you to listen for the announcement of the hot spot company name and booth number. If you’re standing in that booth when the company name is called you will have 60 seconds to enter the booth, stand for one minute, and then exit. You will have two chances to win a $300 cash prize. Two
  - **Hot Spot Cash Drawings!**
  - **Interactive Training Showcase**
  - **No CE credit will be available for these training sessions. Learn directly from top suppliers. These thirty-minute, interactive training sessions on a variety of topics will take place on Sunday and Monday in the training showcase theater!**

**EXHIBIT HALL EVENTS**

**Exhibit/Poster Hall Opening & Welcome Reception—Saturday, June 22 | 6:00–8:00 pm**
Hosted by the SNMMI 2019 Annual Meeting Exhibitors. Packed with the latest trends and technology related to the fields of molecular imaging and nuclear medicine; don’t miss your first chance to network with thousands of industry colleagues, industry leaders, and representatives from major manufacturers in the Exhibit Hall. The Exhibit Hall Grand Opening is the perfect kick-off event for four days of learning and science! Enjoy hors d’oeuvres, drinks, and music. Be sure to visit them all! The Exhibit/Poster Hall will be open from Saturday evening to Tuesday afternoon during the SNMMI Annual Meeting.

**Hot Spot Cash Drawings!**
You will have 6 chances to win a $300 CASH drawing, simply by being in the right booth at the right time. Two drawings will take place each day during Dedicated Exhibit Hall Hours. Be sure to listen for the announcement of the hot spot company name and booth number. If you’re standing in that booth when the company name is called you will be eligible to win the $300 cash prize. Up to 20 companies will be participating – so be sure to visit them all.

**Interactive Training Showcase**
No CE credit will be available for these training sessions. Learn directly from top suppliers. These thirty-minute, interactive training sessions on a variety of topics will take place on Sunday and Monday in the training showcase theater!
SNMMI
Hotel Locator Map

1. Anaheim Hotel
2. Anaheim Marriott
3. Hilton Anaheim
4. Hyatt House at Anaheim Resort/Convention Center
5. Red Lion Hotel Anaheim Resort
6. Sheraton Park Hotel at the Anaheim Resort
7. SpringHill Suites at Anaheim Resort/Convention Center

Built to Last.

Stainless Steel Lead-Lined Cabinetry

Quality and attention to detail is what you expect from Capintec... and that's what you get. Manufactured using only the highest quality materials for a lifetime of reliability, the cabinet's sleek, modern appearance with smooth rounded corners will enhance any hot lab, nuclear medicine department, or PET facility. Capintec's lead-lined cabinetry is available in a multitude of configurations, and designed with your budget in mind.

For over 50 years, Capintec is the company you have relied on and trusted for all of your nuclear medicine product needs. Now, you can rely on Capintec quality for all of your lead-lined cabinetry and radiation shielding products!

For additional information on Capintec Cabinetry, call us at 201-825-9500 or email us at: GetInfo@Capintec.com
### Regular Meeting Registration

<table>
<thead>
<tr>
<th>Registration Type</th>
<th>Member</th>
<th>Nonmember</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician</td>
<td>$780</td>
<td>$1,290</td>
</tr>
<tr>
<td>Scientist</td>
<td>$780</td>
<td>$1,290</td>
</tr>
<tr>
<td>Industry</td>
<td>$780</td>
<td>$1,290</td>
</tr>
<tr>
<td>Technologist</td>
<td>$450</td>
<td>$705</td>
</tr>
<tr>
<td>Laboratory Professional*</td>
<td>$485</td>
<td>$795</td>
</tr>
<tr>
<td>Emeritus-Physician/Scientist</td>
<td>$350</td>
<td>n/a</td>
</tr>
<tr>
<td>Emeritus-Technologist</td>
<td>$215</td>
<td>n/a</td>
</tr>
<tr>
<td>Resident or Post-Doctoral Fellow*</td>
<td>$230</td>
<td>$380</td>
</tr>
<tr>
<td>Technologist Student*</td>
<td>No Charge</td>
<td>$105</td>
</tr>
<tr>
<td>Companion/Guest (11 yrs or older)</td>
<td>$50</td>
<td>$50</td>
</tr>
</tbody>
</table>

### Pre-Reg Registration Rates

<table>
<thead>
<tr>
<th>Registration Type</th>
<th>Member</th>
<th>Nonmember</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member</td>
<td>$890</td>
<td>$1,400</td>
</tr>
<tr>
<td>Nonmember</td>
<td>$890</td>
<td>$1,400</td>
</tr>
<tr>
<td>Member</td>
<td>$890</td>
<td>$1,400</td>
</tr>
<tr>
<td>Nonmember</td>
<td>$890</td>
<td>$1,400</td>
</tr>
</tbody>
</table>

### Onsite Registration Rates

<table>
<thead>
<tr>
<th>Registration Type</th>
<th>Member</th>
<th>Nonmember</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member</td>
<td>$550</td>
<td>$805</td>
</tr>
<tr>
<td>Nonmember</td>
<td>$550</td>
<td>$805</td>
</tr>
<tr>
<td>Member</td>
<td>$595</td>
<td>$905</td>
</tr>
<tr>
<td>Nonmember</td>
<td>$595</td>
<td>$905</td>
</tr>
<tr>
<td>Member</td>
<td>$460</td>
<td>$780</td>
</tr>
<tr>
<td>Nonmember</td>
<td>$460</td>
<td>$780</td>
</tr>
<tr>
<td>Member</td>
<td>$315</td>
<td>$420</td>
</tr>
<tr>
<td>Nonmember</td>
<td>$315</td>
<td>$420</td>
</tr>
<tr>
<td>Member</td>
<td>$340</td>
<td>$490</td>
</tr>
<tr>
<td>Nonmember</td>
<td>$340</td>
<td>$490</td>
</tr>
</tbody>
</table>

### Specialty Workshops

- **Nuclear Medicine Review Course**
  - Saturday-Sunday, June 22-23, 2019
  - Fee: $200

- **Student Technologist Registry Review and Mock Exam**
  - Saturday-Sunday, June 22-23, 2019
  - Fee: $50

### Important Safety Information

#### Warnings and Precautions
- **Risk from radiation exposure**: AZEDRA® contributes to a patient’s overall long-term radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. These risks of radiation associated with the use of AZEDRA® are greater in pediatric patients than in adults. Minimize radiation exposure to patients, medical personnel, and household contacts during and after treatment with AZEDRA® consistent with institutional good radiation safety practices and patient management procedures.
- **Hypothyroidism**: Among the 88 patients who received a therapeutic dose of AZEDRA®, 13% experienced Grade 4 thyroid suppression, 15% experienced Grade 3 thyroid suppression, and 7% experienced Grade 2 thyroid suppression. Five percent of patients experienced febrile neutropenia. Monitor blood cell counts weekly for up to 12 weeks or until tests return to baseline or the normal range. Withhold and dose reduce AZEDRA® as recommended in the prescribing information based on the severity of the hypothyroidism.
- **Secondary myelodysplastic syndrome, leukemia, and other malignancies**: Myelodysplastic syndrome, secondary leukemia, and acute leukemias were reported in 6.5% of the 88 patients who received a therapeutic dose of AZEDRA®. The time to development of NOS or acute leukemia ranged from 2 months to 7 years. Two of the 88 patients developed a non-hematological malignancy.
- **Hypothyroidism**: Hypothyroidism was reported in 14% of the 88 patients who received a therapeutic dose of AZEDRA®. Initiate thyroid blocking medications starting at 1 day before and continuing for 10 days after each AZEDRA® dose to reduce the risk of hypothyroidism or thyroid neoplasia. Evaluate for clinical evidence of hypothyroidism and measure thyroid-stimulating hormone (TSH) levels prior to initiating AZEDRA® and annually thereafter.
- **Elevations in blood pressure**: Eleven percent of the 88 patients who received a therapeutic dose of AZEDRA® experienced an increase in systolic blood pressure to ≥160 mmHg or an increase in diastolic blood pressure to ≥100 mmHg with an increase of 20 mmHg or an increase in diastolic blood pressure to ≥100 mmHg with an increase of 10 mmHg. All changes in blood pressure occurred within the first 24 hours post infusion. Monitor blood pressure daily during the first 24 hours after each therapeutic dose of AZEDRA®.
- **Renal toxicity**: Of the 88 patients who received a therapeutic dose of AZEDRA®, 9% developed renal failure or acute kidney injury and 2% demonstrated a clinically significant decrease in glomerular filtration rate (GFR) measured at 6 or 12 months. Monitor renal function during and after treatment with AZEDRA®. Patients with baseline renal impairment may be at greater risk of toxicity. Perform more frequent assessments of renal function in patients with mild to moderate impairment. AZEDRA® has not been studied in patients with severe renal impairment.
- **Pneumonitis**: Fatal pneumonitis occurred 9 weeks after a single dose in one patient in the expanded access program. Monitor patients for signs and symptoms of pneumonitis and treat appropriately.
- **Embryo-fetal toxicity**: Based on its mechanism of action, AZEDRA® can cause fetal harm. Verify pregnancy status in females of reproductive potential prior to enrolling AZEDRA®. Advise females and males of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment with AZEDRA® and for 6 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 4 months after the final dose.
- **Risk of infertility**: Radiation exposure associated with AZEDRA® may cause infertility in males and females. Radiation absorbed by testes and ovaries from the recommended cumulative dose of AZEDRA® is within the range where temporary or permanent infertility can be expected following external beam radiation therapy.

#### Adverse Reactions

- The most common severe (Grade 3–4) adverse reactions observed in AZEDRA® clinical trials were lymphopenia (16%), neutropenia (11%), thrombocytopenia (10%), anemia (8%), and increases in liver enzymes, lipase, and amylase. Thrombocytopenia was reported in 3% of the 88 patients who received a therapeutic dose of AZEDRA®. Thrombocytopenia (50%), fatigue (26%), and anemia (24%) occurred with an incidence ≥20%. Ten percent of patients discontinued treatment due to adverse reactions. Thrombocytopenia, anemia, lymphopenia, nausea, and vomiting multiple hematologic adverse reactions.

#### Drug Interactions

Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells and therefore interfere with dosimetry calculations or the efficacy of AZEDRA®. These drugs were not permitted in clinical trials that assessed the safety and efficacy of AZEDRA®. Discontinue any agent that reduces catecholamine uptake or depletes catecholamine stores. Monitor patients for evidence of hypothyroidism. Discontinue AZEDRA® if hypothyroidism is confirmed. If hypothyroidism is detected, institute thyroid-blocking medications or thyroid hormone therapy as needed. The use of iodinated contrast media for imaging should be avoided. Radiation exposure associated with AZEDRA® may cause infertility in males and females. Radiation absorbed by testes and ovaries from the recommended cumulative dose of AZEDRA® is within the range where temporary or permanent infertility can be expected following external beam radiation therapy. Patients who have ever received a therapeutic dose of AZEDRA® should use effective contraception during treatment and for 4 months after the final dose. Do not administer these drugs until at least 7 days after each AZEDRA® dose.

For important risk and use information about AZEDRA®, please see Brief Summary of Prescribing Information on adjacent pages.

### Reference

To report suspected adverse reactions, contact Progenics Pharmaceuticals, Inc. at 844-668-3950 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

[Summary of Prescribing Information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/131554s14b label.pdf)

**AZEDRA® is the first and only FDA-approved treatment for patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.**

Patients living with advanced pheochromocytoma and paraganglioma have never had a proven treatment option. **Until AZEDRA®.**

Learn more at www.AZEDRA.com! health-care-providers
Whenever possible, use patient-specific organ masses as recommended.

AZEDRA is indicated for the treatment of adult and pediatric patients age 12 years and older with recurrent or unresectable, locally advanced or metastatic, pheochromocytoma or paraganglioma who would be administered in 2 therapeutic cycles) using the following threshold absorbed-dose (T) shown in Table 1, calculate the total estimated dose (D) using the following:

\[ D = T \times T \]

where:

- \( D \) is the total estimated dose (therapeutic dose: 10 Gy [0.5 Gy x 20 Gy], dosimetry dose: 17.5 Gy [0.5 Gy x 35 Gy])
- \( T \) is the threshold absorbed-dose (T) shown in Table 1

For each 10 kg increase above 50 kg, increase the total estimated dose by 10%.

For patients weighing greater than 50 kg: 185 to 222 MBq (5 or 6 mCi)

Thyroid Blocks and the Pre- and Peri- Concomitant Medications

The following drugs reduce catecholamine uptake or deplete catecholamine stores and should be used for at least three weeks before, during, and for three weeks after dosing with AZEDRA.

Drugs that Reduce Catecholamine Uptake or Deplete Catecholamine Stores

• CNS stimulants or amphetamines (e.g. cocaine, methylphenidate, phenteramine)

Adverse Reactions

The following clinically significant adverse reactions were observed in < 1% to 5% of patients receiving AZEDRA.

Musculoskeletal and Connective Tissue Disorders

- Arthralgia (8%), neck pain (8%)

Endocrine Disorders

- Decreased TSH (5%), hypothyroidism (3%)

Respiratory, Thoracic, and Mediastinal Disorders

- Pulmonary embolism (7%), proteinuria (9%), renal failure (7%)

Gastrointestinal Disorders

- Gastroesophageal reflux disease (6%), stomatitis (3%)

Skin and Subcutaneous Tissue Disorders

- Urticaria (2%), pruritus (1%)

Infections and Infestations

- Pneumonitis • Do not administer the second therapeutic dose of AZEDRA if the first therapeutic dose is associated with a new reference or a significant increase in the inflammatory cells in the pleura or chest wall at the site of administration.

A treatment plan for patients with severe renal impairment (CLcr < 30 mL/min) or end-stage renal disease has not been studied.

Clinical studies of AZEDRA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients.

Adequate and well-controlled studies established in the treatment of this disease were not carried out in geriatric patients. It is generally recognized that geriatric patients tend to have decreased organ function, altered metabolism, and altered response to medication. The safety and effectiveness of AZEDRA in patients with severe renal impairment has not been evaluated.

Adequate and well-controlled studies established in the treatment of this disease were not carried out in children. The safety and effectiveness of AZEDRA in children have not been determined.

Adequate and well-controlled studies established in the treatment of this disease were not carried out in pediatric patients. The safety and effectiveness of AZEDRA in these age categories have not been determined.

Adequate and well-controlled studies established in the treatment of this disease were not carried out in patients with severe renal impairment. The safety and effectiveness of AZEDRA in patients with severe renal impairment has not been determined.

Adequate and well-controlled studies established in the treatment of this disease were not carried out in end-stage renal disease. The safety and effectiveness of AZEDRA in patients with end-stage renal disease has not been determined.
A global leader…
in the field of Medical Imaging

XENON
Xe 133 Gas

For more information, contact Lantheus Medical Imaging Customer Service at 1-800-299-3431
Please see Full Prescribing Information at www.lantheus.com

Brands you know.
Quality you trust.
SAVE $100 WHEN YOU REGISTER BEFORE
June 20, 2019
Finalize Your Plans for Anaheim Today
snmmi.org/2019preview2

SNMMI: Advancing Precision Medicine